These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27098897)

  • 21. Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort.
    Sidovar MF; Limone BL; Coleman CI
    Patient Relat Outcome Meas; 2016; 7():13-8. PubMed ID: 26893584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An empirical comparison of the OPQoL-Brief, EQ-5D-3 L and ASCOT in a community dwelling population of older people.
    Kaambwa B; Gill L; McCaffrey N; Lancsar E; Cameron ID; Crotty M; Gray L; Ratcliffe J
    Health Qual Life Outcomes; 2015 Sep; 13():164. PubMed ID: 26420314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating health related quality of life effects in vitiligo. Mapping EQ-5D-5 L utilities from vitiligo specific scales: VNS, VitiQoL and re-pigmentation measures using data from the HI-Light trial.
    Begum R; Crott R; Martina R; Loizidou EM; Khan I
    Health Qual Life Outcomes; 2023 Aug; 21(1):85. PubMed ID: 37563643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer.
    Skaltsa K; Longworth L; Ivanescu C; Phung D; Holmstrom S
    Value Health; 2014 Mar; 17(2):238-44. PubMed ID: 24636382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping the COPD Assessment Test onto EQ-5D.
    Hoyle CK; Tabberer M; Brooks J
    Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
    Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
    J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly.
    Badia X; Trainer P; Biermasz NR; Tiemensma J; Carreño A; Roset M; Forsythe A; Webb SM
    J Med Econ; 2018 Apr; 21(4):382-389. PubMed ID: 29261359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial.
    Marciniak CM; Toledo S; Lee J; Jesselson M; Bateman J; Grover B; Tierny J
    World J Gastroenterol; 2014 Nov; 20(43):16323-33. PubMed ID: 25473191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does the choice of tariff matter?: A comparison of EQ-5D-5L utility scores using Chinese, UK, and Japanese tariffs on patients with psoriasis vulgaris in Central South China.
    Zhao Y; Li SP; Liu L; Zhang JL; Chen G
    Medicine (Baltimore); 2017 Aug; 96(34):e7840. PubMed ID: 28834893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients.
    Kiadaliri AA; Eliasson B; Gerdtham UG
    Health Qual Life Outcomes; 2015 Sep; 13():145. PubMed ID: 26374709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The responsiveness of quality of life utilities to change in depression: a comparison of instruments (SF-6D, EQ-5D, and DFD).
    Gerhards SA; Huibers MJ; Theunissen KA; de Graaf LE; Widdershoven GA; Evers SM
    Value Health; 2011; 14(5):732-9. PubMed ID: 21839412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the diversity and determinants of health-related quality of life measures in patients with acute heart failure.
    Patil D; Tang HJ; Kuo FH; Toh HS; Yang IN; Chang WT; Lee MC; Chung KN; Huang CY; Hsu WH; Chang TC; Shih JY; Liao CT
    ESC Heart Fail; 2024 Aug; 11(4):1963-1970. PubMed ID: 38509031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer's disease scale: development and results from a mapping study.
    Rombach I; Iftikhar M; Jhuti GS; Gustavsson A; Lecomte P; Belger M; Handels R; Castro Sanchez AY; Kors J; Hopper L; Olde Rikkert M; Selbæk G; Stephan A; Sikkes SAM; Woods B; Gonçalves-Pereira M; Zanetti O; Ramakers IHGB; Verhey FRJ; Gallacher J; Actifcare Consortium ; LeARN Consortium ; Landeiro F; Gray AM;
    Qual Life Res; 2021 Mar; 30(3):867-879. PubMed ID: 33068236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translating Clinical Findings into the Patient's Perspective: Post-hoc Pooled Analysis of Bowel Movement Changes as a Predictor of Improvement in Patients' Opioid-induced Constipation Symptoms and Outcomes.
    Coyne KS; Poon JL; Thompson C; Hu Y; Datto CJ; Sostek M
    Clin Ther; 2017 Jan; 39(1):75-88. PubMed ID: 27938897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mapping EQ-5D utilities to GBD 2010 and GBD 2013 disability weights: results of two pilot studies in Belgium.
    Maertens de Noordhout C; Devleesschauwer B; Gielens L; Plasmans MHD; Haagsma JA; Speybroeck N
    Arch Public Health; 2017; 75():6. PubMed ID: 28191312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the Quality of Life and Health-Related Quality of Life of Patients With End-Stage Kidney Disease Resulting From Kidney Transplantation Using the Kidney Disease Quality of Life-Short Form and EuroQOL-5 Dimension-5 Level Questionnaires.
    Sawada A; Hiragi S; Tamura H; Goto R; Matsuyama Y; Sakai K; Miyata H; Yanagita M; Kuroda T; Ogawa O; Kobayashi T
    Transplant Proc; 2021 Apr; 53(3):881-884. PubMed ID: 33303208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies.
    Levy M; Haycox AR; Becker U; Costantino C; Damonte E; Klingelschmitt G; von Büdingen HC; Wallenstein G; Maio DD; Szczechowski L
    Mult Scler Relat Disord; 2022 Jan; 57():103332. PubMed ID: 35158426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of FACT- and EQ-5D-based utility scores in cancer.
    Pickard AS; Ray S; Ganguli A; Cella D
    Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating EQ-5D utilities based on the Short-Form Long Term Conditions Questionnaire (LTCQ-8).
    Tsiachristas A; Potter CM; Rocks S; Peters M; Cundell M; McShane R; Batchelder L; Fox D; Forder JE; Jones K; Waite F; Freeman D; Fitzpatrick R
    Health Qual Life Outcomes; 2020 Aug; 18(1):279. PubMed ID: 32795317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.